NattoPharma with strong growth in the first quarter

Oslo, Norway (30 April 2019)

NattoPharma increased revenues by 41% in the first quarter and delivered a positive adjusted EBITDA of NOK 1,9 million.

“We are pleased to deliver a strong first quarter. We continue to demonstrate our ambition of profitable growth which is a result of the increased focus in the organization in the last two to three years.

In the quarter we continued our investments in future growth and profitability with the synthetic K2 development project, where we anticipate initial results during Q2. We also see increasing demand in the market and are working relentlessly to capture a part of this growth through sales and marketing efforts and product offerings. We believe we are on track to deliver in the upper parts of previous guiding with an annual revenue growth of 30-35% and gross margins of 40-45%”

Financial highlights:

(mnok) Q1’19  Q1’18  Change  2018 
Product Revenue  27,8 19,8  8,0 (+41%)  101,7 
Gross Margin  44,1%  41,3%  +2,7% 43,1%
EBITDA (adj.)  1,9  0,4  1,5 6,7 
EBT -0,4  -3,5  3,1  1,8 

Please find enclosed the Nattopharma Group First Quarter 2019 Report.

For more information, please contact:

Kjetil Ramsøy

CEO, NattoPharma


This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. 


About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.